Class dossier · Bioregulator · Draft
Bioregulators
Walk into any pharmacy in St. Petersburg and you can buy, over the counter, a calf-thymus extract invented for Soviet soldiers in the 1970s. Down the street, a synthetic four-amino-acid peptide — advertised as a geroprotector — sits on the same shelf. Both come from the same institute, the work of one man who ran it for forty years: Vladimir Khavinson, who died in January 2024. What follows is the catalogue of what he left behind. There are twenty-six compounds in the corpus: the older complex extracts (Thymalin from calf thymus, Epithalamin from bovine pineal, Cortexin from pig-brain cortex, Prostatilen from bovine prostate, Retinalamin from mammalian retina) and the newer short synthetic peptides his group characterised in the 1990s and 2000s (Epitalon, the four-amino version of Thymalin's active fragment; Thymogen, the dipeptide; Pinealon, Pancragen, Cortagen, Livagen, Cardiogen, the rest). The mechanism the school claims — that short peptides bind DNA in the major groove and re-program tissue-specific gene expression — has three pieces of independent-looking evidence (transporter-mediated uptake shown by in-silico docking in 2023, nuclear penetration observed by microscopy in 2011, and a direct NMR-plus-molecular-dynamics binding study of the EDR tripeptide in 2019). The bigger claims — twenty to forty percent rodent lifespan extension, telomere elongation in human cell lines — come almost entirely from Khavinson's own group, in journals most Western readers have never heard of. There is one near-independent replication: Brunel University London ran an Epitalon dose-response on human cell lines in 2025, with positive results and a figure-files-only correction. That is the highest the evidence gets without leaving the building.
1 · Definition
- Definition
- A peptide bioregulator is a di-, tri-, or tetrapeptide (or organ-derived polypeptide complex) claimed to preferentially modulate gene expression in the organ from which it was originally isolated. The class is defined by claimed mechanism, not by a molecular target.
- Criteria
- Isolated from a specific organ (tier 1) or identified by HPLC within such a complex (tier 2); Claimed organ-specific transcriptional effect on the source organ; Di-/tri-/tetrapeptide sequences show a strong Glu-Asp-X family motif with a C-terminal residue encoding tissue association
2 · Provenance
- Institution
- —
- Organizations
- S.M. Kirov Military Medical Academy (Военно-медицинская академия им. С.М. Кирова), Leningrad/St. Petersburg — the Morozov+Khavinson lab · Saint Petersburg Institute of Bioregulation and Gerontology (Северо-Западное отделение РАМН), founded 1992 by Khavinson · Cytomed / Samson-Med / Герофарм (commercial holders of the registered products)
- Key people
- Vladimir Khavinson (В.Х. Хавинсон, 27 Nov 1946 Cottbus – 6 Jan 2024 St. Petersburg; ~459 PubMed-indexed papers as of 2026-08-26, up from ~380 in the May 2026 reference; Colonel of Medical Service; 196 patents, 775 publications); Vyacheslav Morozov (В.Г. Морозов) — co-developer of Thymalin, Thymogen, Vilon; originator of the cytomed extraction protocol (US Patent 5,070,076, 1991); Valery Anisimov (N.N. Petrov Oncology, gerontoprotector lifespan studies, co-author)
- Intellectual lineage
- Pavlov (nervism / trophic innervation) → Speransky (neurodystrophic process theory) → Bogomolets (connective-tissue physiology, anti-reticular cytotoxic serum, 1938 Kyiv longevity conference) → Filatov (biogenic stimulators doctrine, placenta extract, tissue therapy) → Asatiani G.I. (1957 mid-century consolidation of tissue-therapy corpus) → Khavinson + Morozov (1971–2013 peptide bioregulators). Documented in (2026-08-27). The Kuhn/Sandor '1920s German endogenous-bioregulator school' sometimes cited by Khavinson-school papers is best treated as a claimed but weakly-documented Western pedigree — Stambler 2014 flags it as anachronistic.
- COI note
- Single-PI-dominated literature; the discovery principal is also the principal commercial beneficiary. Structural COI of the kind that normally demands independent replication for any claim to count. Morozov's posthumous role is acknowledged but his papers are fewer than Khavinson's in current indexing.
3 · Mechanism — claim by claim
01
The peptides can enter cells via LAT1/LAT2/PEPT1 transporters
2023 Biomolecules, Russian-Israeli consortium. Docking/modelled accommodation of 26 named sequences; active sequences bind more strongly than inactive dipeptide controls but less reliably than known substrates. No live-cell transporter-knockout validation.
02
At least one bioregulator tripeptide reaches the cell nucleus
Biochemistry (Moscow) 2011, Fedoreyeva/Kireev/Khavinson/Vanyushin. FITC-labelled Epithalon, Pinealon, Testagen: fluorescence in cytoplasm, nucleus and nucleolus of HeLa cells. (Citation corrected 2026-08-26 — the working reference's 21692752 is an unrelated paper.)
03
EDR (Pinealon) binds DNA in the major groove
J Phys Chem B 2019: NMR, viscosimetry, UV-Vis, MD. Partial major-groove insertion, contacts guanine N7/O6, modulated by divalent cations. Most methodologically rigorous mechanism work in the field.
04
Epitalon (AEDG) induces hTERT/telomerase and telomere elongation in human somatic cells
Foundational: 2003 Bull Exp Biol Med (Khavinson group). 2004 follow-up: 10 extra divisions beyond Hayflick limit. 2025 Biogerontology (Brunel U London, no Khavinson co-authorship): dose-dependent telomere extension via hTERT upregulation (normal cells) or ALT activation (breast-cancer lines). Nov-2025 correction is figure-files-only (Figs 1–3 wrong image files); captions and conclusions unchanged. Caveat: corrected panels not pixel-verified against captions.
05
Each peptide is tissue-specifically gene-regulatory
Rests on the 2001 Bull Exp Biol Med tissue-specificity paper (~7 cites) and downstream microarray work from the same institute. No high-IF independent replication. This is the load-bearing headline claim and the least-supported piece.
06
Bioregulators extend rodent lifespan 20–40%
Best individual study: Anisimov/Khavinson 2000 Biogerontology (Glu-Trp/Thymogen): 76 rats, 5 µg sc 5×/week × 12 months; mean lifespan unchanged, 10% maximum-survivor cohort +949d→1048d (p<0.001); Gompertz alpha 0.0071→0.0041/day. The '20–40%' figure is an aggregation across compounds, not a single result.
07
Clinical utility (immunodeficiency, post-stroke, etc.)
Cortexin: 42 PubMed-classified clinical trials (name-collision noise makes the real signal smaller). Thymalin: ~30 years of Russian field use. Epitalon: 1 PubMed-classified clinical trial; sold as nutraceutical/compounded, not registered.
4 · Roster — live-verified identities
| Name | Seq | Tissue | Formula | MW | CID | Verified |
|---|---|---|---|---|---|---|
| Epitalon | AEDG | Pineal | C14H22N4O9 | 390.35 | 219042 | verified |
| Thymogen | EW | Thymus | C16H19N3O5 | 333.34 | 100094 | verified |
| Vilon | KE | Thymus | C11H21N3O5 | 275.3 | 7010502 | verified |
| Pinealon | EDR | Pineal | C15H26N6O8 | 418.4 | 10273502 | verified |
| Prostamax | KEDP | Prostate | C20H33N5O9 | 487.5 | 9848296 | verified |
| Cortagen | AEDP | Brain cortex | — | 430.4 | 18439621 | found live 2026-08-26 (missing from working reference) |
| Livagen | KEDA | Liver | — | 461.5 | 87919683 | found live 2026-08-26 (missing from working reference) |
| Bronchogen | AEDL | Lung | — | 446.5 | 11690869 | found live 2026-08-26 (missing from working reference) |
| Cardiogen | AEDR | Heart | — | — | — | PUBCHEM NAME-TRAP: name search returns CID 10917 (MW 161, unrelated small molecule). No trustworthy CID; treat as unverified. |
| Pancragen | KEDW | Pancreas | — | — | — | sequence-only (literature); no PubChem entry found live |
| Thymalin | — | Thymus | — | — | — | calf-thymus polypeptide preparation; registered drug (RU/CIS) — immunodeficiency, post-op, sepsis adjuvant, burns, asthenia. Representative-component CID 3085284. |
| Epithalamin | — | Pineal | — | — | — | pineal polypeptide preparation; source complex for Epitalon |
| Cortexin | — | Brain cortex | — | — | — | largest commercial bioregulator by Russian prescription volume: stroke, TBI, cerebrovascular disease, neonatal hypoxic encephalopathy, epilepsy adjuvant, cognitive decline |
5 · Lab signal — live OpenAlex counts
| Query | Count |
|---|---|
| Khavinson peptides | 553 |
| peptide bioregulators | 1589 |
| epitalon | 929 |
| cortexin | 2483 |
| epithalamin | 149 |
| thymalin | 478 |
| vilon | 250 |
| pinealon | 61 |
| cortagen | 32 |
| livagen | 29 |
| bronchogen | 68 |
| хавинсон | 182 |
| эпиталон | 16 |
| кортексин | 160 |
Cyrillic 'хавинсон' yields 182 (not 7 as the May reference claimed) — Cyrillic coverage is much better than the working reference assumed.
6 · Structural problems with the evidence
- Single-PI dominance: ~459 PubMed papers list Khavinson (2026-08-26 live count)
- Venue concentration: Bulletin of Experimental Biology and Medicine (RU, low IF), Neuroendocrinology Letters (SK, low IF), Advances in Gerontology (RU, very low IF); high-IF placements are rare
- Commercial COI concentrated at one institute around one PI
- No high-profile Western group has run the headline experiments under a rigorous protocol (e.g. NIA ITP) with a public result — the field remains a closed loop to outsiders
- Mainstream review coverage is emerging but is the field entering on its own terms: 2026 Frontiers in Aging (PMID 42021992) and 2020 Stem Cell Rev Rep (PMID 31808038, Khavinson-authored) are not skeptical reviews
7 · What would shift the evidence
- A blinded, powered rodent lifespan study under NIA ITP protocol with Epitalon + one synthetic tetrapeptide
- Independent CRISPR/transporter-knockout validation of the LAT/PEPT uptake mechanism
- Independent telomerase-induction replication in a Western academic lab (the 2025 Brunel result is the first and only such data point)
- PK profiling of bromantane-grade rigour: plasma + tissue PK after defined injection/oral/intranasal dosing
- Pixel-level comparison of the corrected Figs 1–3 in the 2025 Biogerontology paper against their captions
8 · Corroboration
- Verified
- 2026-08-27
- Method
- Every PMID cross-verified against live PubMed; two citation errors caught and corrected in the dossier.
- Supply chain 2026-08
- Samson-Med (manufacturer of Thymalin) **stopped manufacturing thymalin October 2025**. Russian registration ЛС-000267 remains active (expires 18.12.2027, re-issued 19.04.2023, holder Цитомед); new St. Petersburg manufacturing facility reported 76% complete by summer 2026. Per Twitter/X intel (Aug 2026): gray-market 'THYMALIN 10mg 99% purity' research-chem product is NOT pharmacologically equivalent to original Samson-Med thymalin — polypeptide fraction ≠ defined peptide. Compound remains obtainable in Russia while registration is active but Western supply chains (Cosmic Nootropic, etc.) are degrading.
- Disambiguation
- THYMALIN ≠ THYMULIN — these are two completely different molecules and must not be conflated. Thymalin = Soviet (Khavinson / Samson-Med) calf-thymus polypeptide fraction; the Russian studies on Thymalin are about this fraction. Thymulin = a French-isolated zinc-binding nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, with Zn²⁺) characterized by J.-F. Bach in 1977; it is a thymic hormone candidate but a structurally and pharmacologically different molecule from Thymalin. Khavinson's peptide bioregulator corpus is **Thymalin only** — any claim of 'thymulin from a Khavinson paper' is conflating different molecules. (Source: @AbudBakri MD, X/Twitter, 1d/36K views, 2026-08-27.)
9 · Open questions
- Build a structured NON-Khavinson author corpus (Mironov, Vinogradova, Polyakova, Stark) to quantify independent primary work
- Pull LAT/PEPT docking energies from the 2023 Biomolecules supplement; test whether scores predict the organ-specificity ranking
- Cross-check the 2026 Frontiers in Aging epitalon coverage against primary literature
- Map regulatory status RU/BY/KZ + EU nutraceutical market